Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

2.53
-0.0350-1.37%
Volume:1.56M
Turnover:4.08M
Market Cap:211.37M
PE:-0.83
High:2.75
Open:2.63
Low:2.52
Close:2.56
Loading ...

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Motley Fool
·
28 Jun

JonesTrading Sticks to Their Hold Rating for Editas Medicine (EDIT)

TIPRANKS
·
17 Jun

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Motley Fool
·
17 Jun

Editas says levels of HBG1/2 promoter editing in hematopoietic stem cells

TIPRANKS
·
12 Jun

Editas Medicine Announces Breakthrough in In Vivo Gene Editing for Sickle Cell Disease and Beta Thalassemia at European Hematology Association 2025 Congress

Reuters
·
12 Jun

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables in Vivo Hbg1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

THOMSON REUTERS
·
12 Jun

Editas Medicine Inc - Achieves 58% Mean Editing at Five Months After Single Dose

THOMSON REUTERS
·
12 Jun

Editas Medicine Inc. EVP and Chief Scientific Officer Linda Burkly Reports Disposal of Common Shares

Reuters
·
05 Jun

Editas Medicine CEO Neil O'Neill Reports Disposal of Common Shares

Reuters
·
05 Jun

Editas Medicine Inc. Conducted Annual Stockholders Meeting

Reuters
·
03 Jun

Editas Medicine Inc. Unveils Innovative Gene Editing Strategies to Transform Therapeutics Globally

Reuters
·
29 May

Cautious Outlook on Editas Medicine: Hold Rating Amidst Preclinical Progress and Financial Considerations

TIPRANKS
·
17 May

Promising Preclinical Data and Market Opportunities Drive Buy Rating for Editas Medicine

TIPRANKS
·
16 May

BRIEF-Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas’ Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting

Reuters
·
14 May

Editas Medicine Announces Promising Preclinical Results for In Vivo Gene Editing Approach to Treat Sickle Cell Disease and Beta Thalassemia

Reuters
·
14 May

Editas Medicine Reports New in Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in Hscs at the American Society of Gene and Cell Therapy Annual Meeting

THOMSON REUTERS
·
14 May

Editas Medicine Is Maintained at Outperform by Baird

Dow Jones
·
13 May

Editas Medicine Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Editas Medicine Q1 EPS $(0.92) Misses $(0.59) Estimate, Sales $4.66M Beat $706.00K Estimate

Benzinga
·
13 May

Editas Medicine Inc. to Showcase Preclinical Gene Editing Advances at ASGCT Annual Meeting

Reuters
·
13 May